New Imcivree Indication; Top Pediatric Endo Hospitals; Contrast Dye & Tots’ Thyroids

The FDA approved a new indication for setmelanotide (Imcivree), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome but rejected a new indication for Alström syndrome, Rhythm Pharmaceuticals announced.

The endocrine-disrupting chemicals PFOA and PFOS may be more harmful than previously thought, the Environmental Protection Agency warned. (AP)

According to a recent survey of U.S. adults, 79% said paying for insulin created a financial burden for them, even requiring taking on debt in some cases. (Forbes)

The Children’s Hospital of Philadelphia took the top spot on U.S. News & World Report‘s 2022-2023 top hospitals for pediatric diabetes & endocrinology. The #2 and #3 spots went to Boston Children’s Hospital and Cincinnati Children’s Hospital Medical Center, respectively.

After accidentally being exposed to his father’s testosterone gel, a 2-year-old boy began showing signs of puberty. (New York Post)

Pushing back on the FDA’s recent guidance recommending that children under 3 be monitored for hypothyroidism after exposure to intravascular iodine-containing contrast material, the American College of Radiology said there is “no convincing scientific evidence” at this time to support this kind of testing. (Journal of the American College of Radiology)

Compared with a traditional family-based behavioral treatment delivered in an academic center, a less intense guided self-help program delivered in the primary care setting was just as effective at reducing BMI in kids. (Pediatrics)

A 30-year Australian study found that greater fitness in childhood was linked with better cognition in midlife. (Journal of Science and Medicine in Sport)